Sequential re-rating: management describes the same offering landing bigger the second and third time around
The model's full reasoning — Q2 2021 call → NOWe need to determine if management describes successive engagements of the same kind coming in at progressively larger size. The question asks about deals, orders, contracts, projects, etc. In the transcript, management discusses drilling campaigns, workovers, FPSO contracts, Block P development, etc. But does management convey that the size of these engagements is escalating? For example, the drilling campaign: they have a program with two development wells and two appraisal wellbores with options to drill additional wells. They mention potential fifth well. But is that an escalation in size compared to past? They don't compare to past drilling campaigns in terms of size. They mention that they are generating significant cash flow and have hedges. The FPSO contract: they are in talks to finalize a binding agreement that will reduce costs, not increase size. The Block P development: they are moving forward with a field development concept, but no comparison to past. The workovers: they are doing two workovers in Q3 instead of one, but that's more volume, not necessarily larger unit size. The question specifically asks about "successive engagements of the same kind" coming in at "progressively larger size." Management does not explicitly state that the size of contracts, orders, or projects is escalating. They talk about growth through acquisitions and drilling, but not about the unit size of repeatable business increasing. For example, they mention the Sasol acquisition increased production, but that's a one-time acquisition. They don't say that new deals are bigger than previous ones. They mention options to drill additional wells, but that's optionality, not a confirmed escalation. They also mention that they are evaluating a fifth well, but that's not a statement of progressive size. The transcript does not contain a clear statement from management that the size of what they are landing now is larger than what they landed before for the same offering. They talk about growth, but not about unit size escalation. Therefore, the answer is NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ASO | Academy Sports and Outdoors, Inc. | Q1 2024 | 2024-06-11 | C+ |
| AKYA | Akoya Biosciences, Inc. | Q2 2023 | 2023-08-07 | C+ |
| SPT | Sprout Social, Inc. | Q2 2023 | 2023-08-04 | B+ |
| SGRY | Surgery Partners, Inc. | Q2 2022 | 2022-08-02 | B+ |
| CYBR | CyberArk Software Ltd. | Q3 2021 | 2021-11-04 | B+ |
| ASAN | Asana, Inc. | Q2 2022 | 2021-09-01 | B+ |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
AKYA · Q2 2023 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing a clear pattern of escalating project sizes in the translational/clinical space. Brian notes a migration from exploratory studies (reasonable size) to larger retrospective studies and even larger retrospective-prospective ongoing clinical studies, with projects moving "further and further downstream.
ASAN · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES Management describes exactly this pattern. Dustin notes the company is “closing larger deals and expanding seats across departments and geographies quickly in large organizations,” and that the growth in the >$50k cohort “reflected an acceleration in our largest enterprise customers.
SGRY · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing exactly this pattern for physician recruiting cohorts. Wayne notes that the 2022 cohorts are “no exception to this trend, bringing more cases with a higher overall net revenue per case than our 2021 cohorts did in the same period last year.